OS Therapies (OSTX) Change in Accured Expenses (2023 - 2026)
OS Therapies' (OSTX) quarterly Change in Accured Expenses came in at $3.9 million in Q1 2026, up 4103.06% YoY from $92371.9 in Q1 2025, and up 280.8% on a QoQ basis from $1.0 million in Q4 2025.
OS Therapies (OSTX) Change in Accured Expenses (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Change in Accured Expenses data on file, last reported at $3.9 million in Q1 2026.
- Quarterly Change in Accured Expenses rose 4103.06% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 5410.83% YoY) and the FY2025 annual result came in at $893992.0, up 1946.21% from the prior year.
- Change in Accured Expenses grew to $3.9 million in Q1 2026, from $1.0 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $3.9 million in Q1 2026 to a low of -$182323.0 in Q4 2024.
- A 4-year average of $375039.8 and a median of $15140.0 in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses slumped 636.46% — and 2026, when it surged 4103.06%.
- Tracing OSTX's Change in Accured Expenses over 4 years: stood at $162500.0 in 2023, then slumped by 212.2% to -$182323.0 in 2024, then jumped by 659.2% to $1.0 million in 2025, then surged by 280.8% to $3.9 million in 2026.
- The last three Change in Accured Expenses figures came in at $3.9 million (Q1 2026), $1.0 million (Q4 2025), and $15140.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | OS Therapies | 19.46 Mn | 19.46 Mn | - | 5.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.88 Mn |
| Mar 31, 2026 | 3.88 Mn |
| Dec 31, 2025 | 1.02 Mn |
| Dec 31, 2025 | 1.02 Mn |
| Sep 30, 2025 | 15,140.00 |
| Sep 30, 2025 | 15,140.00 |
| Jun 30, 2025 | -43,713.00 |
| Jun 30, 2025 | -43,713.00 |
| Mar 31, 2025 | -96,987.00 |
| Mar 31, 2025 | -96,987.00 |
| Dec 31, 2024 | -182,323.00 |
| Dec 31, 2024 | -182,323.00 |
| Sep 30, 2024 | 165,146.00 |
| Sep 30, 2024 | 165,146.00 |
| Jun 30, 2024 | 22,400.00 |
| Jun 30, 2024 | 22,400.00 |
| Mar 31, 2024 | -53,646.00 |
| Mar 31, 2024 | -53,646.00 |
| Dec 31, 2023 | 162,500.00 |
| Dec 31, 2023 | 162,500.00 |